Wall Street analyst firm Piper Jaffary has raised its target price on Inspire Pharmaceutical stock to $25.

Inspire (Nasdaq: ISPH) opened trading Monday at $19.50 but dropped 30 cents by midday.

Piper Jaffary said the price target reflects a “lower risk profile” for the stock based on positive news about Inspire’s diquafosol drug for treatment of dry eye.

Inspire: www.inspirepharm.com